C arotid-artery atherosclerosis is an important cause of ischemic stroke. 1 Carotid endarterectomy has been established as effective treatment for both symptomatic patients and asymptomatic patients. [2] [3] [4] Carotid-artery stenting is another option for treatment. The results of randomized trials comparing carotid-artery stenting and carotid endarterectomy for use in symptomatic patients are conflicting. [5] [6] [7] The primary aim of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) was to compare the outcomes of carotid-artery stenting with those of carotid endarterectomy among patients with symptomatic or asymptomatic extracranial carotid stenosis.
Me thods

Study Design
CREST is a randomized, controlled trial with blinded end-point adjudication. Ethics review boards at all participating centers approved the protocol. All patients provided written informed consent. The authors designed the study, gathered and analyzed the data, wrote the manuscript, made the decision to publish the findings, vouch for the completeness and accuracy of the data, and attest to the fidelity of the report to the study protocol. Abbott Vascular Solutions (formerly Guidant) donated the Accunet and Acculink systems to all CREST centers in Canada and to CREST centers in the United States that were at Veterans Affairs sites. Abbott has a nonvoting seat on the CREST Executive Committee and reviewed the final draft of the manuscript before submission. Abbott assisted with CREST site monitoring and was responsible for all site monitoring of the Canadian centers. The full protocol and statistical analysis plan can be found in the Supplementary Appendix with the full text of this article at NEJM.org.
Centers and Investigators
We enrolled patients at 108 centers in the United States and 9 in Canada. Centers were required to have a team consisting of a neurologist, an interventionist, a surgeon, and a research coordinator. Patients could not be randomly assigned to a treatment group until the operators performing carotidartery stenting and carotid endarterectomy had been certified. Certification was achieved by 477 surgeons, whose clinical results were audited by means of a validated selection process 8 documenting that they performed more than 12 procedures per year and that the rates of complications and death were less than 3% among asymptomatic patients and less than 5% among symptomatic patients. The 224 interventionists were certified after satisfactory evaluation of their endovascular experience, carotid-stenting results, participation in hands-on training, and participation in a leadin phase of training (see additional details in the Supplementary Appendix). 9
Selection of Study Patients
Patients were considered to be symptomatic if they had had a transient ischemic attack, amaurosis fugax, or minor nondisabling stroke involving the study carotid artery within 180 days before randomization. Eligibility criteria were stenosis of 50% or more on angiography, 70% or more on ultrasonography, or 70% or more on computed tomographic angiography or magnetic resonance angiography if the stenosis on ultrasonography was 50 to 69%. Eligibility was extended in 2005 to include asymptomatic patients, for whom the criteria were stenosis of 60% or more on angiography, 70% or more on ultrasonography, or 80% or more on computed tomographic angiography or magnetic resonance angiography if the stenosis on ultrasonography was 50 to 69%. Patients were excluded if they had had a previous stroke that was sufficiently severe to confound the assessment of end points or if they had chronic atrial fibrillation, paroxysmal atrial fibrillation that had occurred within the preceding 6 months or that necessitated anticoagulation therapy, myocardial infarction within the previous 30 days, or unstable angina. Additional eligibility criteria were clinical and anatomical suitability, before randomization, for management by means of either of the study revascularization techniques. The full eligibility criteria have been published elsewhere. 10
Stenting and Endarterectomy
Carotid-artery stenting and carotid endarterectomy were performed according to published guidelines. 9, 11, 12 For carotid-artery stenting, the protocol specified use of the RX Acculink stent and, whenever feasible, the RX Accunet embolic-protection device. At least 48 hours before carotidartery stenting, patients received aspirin, at a dose of 325 mg twice daily, and clopidogrel at a dose of 75 mg twice daily. When carotid-artery stenting was scheduled for within 48 hours after randomization, 650 mg of aspirin and 450 mg of clopidogrel were given 4 or more hours before the procedure. After the procedure, patients received one or two 325-mg doses of aspirin daily for 30 days and either clopidogrel, 75 mg daily, or ticlopidine, 250 mg twice daily, for 4 weeks. The continuation of antiplatelet therapy for more than 4 weeks after the procedure was recommended for all patients who had undergone carotid-artery stenting. At Patients were assessed for eligibility before randomization, but the number of patients assessed is not available, because screening logs were not maintained. CAS denotes carotid-artery stenting, and CEA carotid endarterectomy.
least 48 hours before carotid endarterectomy, patients received 325 mg of aspirin daily and continued to receive that dose for a year or more. Alternatives to this regimen were ticlopidine given at a dose of 250 mg twice daily, clopidogrel at a dose of 75 mg daily, aspirin at a dose of 81 mg daily, or aspirin and extended-release dipyridamole twice daily ( Table 1 in the Supplementary Appendix). Patients undergoing either study procedure received medical therapy that was consistent with the current standard of care, including treatment of hypertension and hyperlipidemia.
Follow-up Assessments of End Points
Neurologic evaluation was performed at baseline and 18 to 54 hours after the study procedure, 1 month afterward, and every 6 months thereafter.
The evaluation consisted of the use of the National Institutes of Health (NIH) Stroke Scale (NIHSS), 13 the modified Rankin scale, and the Transient Ischemic Attack (TIA)-Stroke Questionnaire. 14 The NIHSS is a 15-item neurologic-impairment scale, with possible scores ranging from 0 (no deficit) to 42 (quadriplegia and coma). The modified Rankin scale is a disability scale on which scores can range from 0 (no symptoms) to 6 (death). The TIA-Stroke Questionnaire consists of a question about whether there is a history of TIA, one about whether there is a history of stroke, and six questions about whether there was a sudden onset of any of various focal neurologic symptoms consistent with TIA or stroke. Cardiac-enzyme levels were measured before the study procedure and 6 to 8 hours after the procedure. Electrocardiography (ECG) was performed before stenting or endarterectomy, as well as 6 to 48 hours and 1 month afterward. Carotid ultrasonography was performed before the study procedure; 1, 6, and 12 months afterward; and annually thereafter. 10 A follow-up telephone interview, including administration of the TIA-Stroke Questionnaire, 14 was conducted at 3 months and every 6 months thereafter. General health status was assessed at baseline, at 2 weeks, 1 month after the procedure, and 1 year after randomization, with the use of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), which evaluates eight dimensions of health, with scores for each ranging from 0 to 100, and higher scores indicating better health status. The SF-36 provides summary scales for overall physical and mental health, with norm-based standardization of the scores to a mean of 50 and a standard deviation of 10. 15,16 The primary end point was the composite of any stroke, myocardial infarction, or death during the periprocedural period or ipsilateral stroke within 4 years after randomization. When the procedure was performed within 30 days after randomization, the periprocedural period was defined as the period from randomization through 30 days after the procedure. When the procedure was not performed within 30 days after randomization, the periprocedural period was defined as the period from randomization through 36 days after randomization. Study committees unaware of the treatment assignments adjudicated stroke and myocardial infarction.
Stroke was defined as an acute neurologic event with focal symptoms and signs, lasting for 24 hours or more, that were consistent with focal cerebral ischemia. The adjudication process was initiated after a clinically significant neurologic event, any positive response on the TIA-Stroke Questionnaire, or an increase by 2 points or more in the NIHSS score. Stroke was defined as major stroke on the basis of clinical data or if the NIHSS score was 9 or higher 90 days after the procedure. Myocardial infarction was defined by a creatine kinase MB or troponin level that was twice the up- per limit of the normal range or higher according to the center's laboratory, in addition to either chest pain or symptoms consistent with ischemia or ECG evidence of ischemia, including new STsegment depression or elevation of more than 1 mm in two or more contiguous leads according to the core laboratory. 17
Statistical Analyses
Analyses were aimed at testing for superiority. The null hypothesis was that the two study treatments are equivalent; the alternative hypothesis was that the treatments differ. A sample size of 2500 patients was selected to provide a statistical power of 90% to detect a hazard ratio for the primary end point of less than 0.54 or more than 1.49 with stenting as compared with endarterectomy, approximating an absolute difference of 1.2 percentage points per year in the rate of the primary end point between the two treatment groups. Intention-to-treat survival analysis was used, and Kaplan-Meier survival curves were plotted. Two interim analyses were performed with the use of O'Brien-Fleming boundaries, 18 the first after approximately one fifth of the patients had been recruited, and the second after approximately half the patients had been recruited. Multiple-imputation techniques 19 were used to assess bias from * The periprocedural period was defined, according to the study protocol, as the 30-day period after the procedure (for all patients who underwent the assigned procedure within 30 days after randomization) or the 36-day period after randomization (for all patients who did not undergo the assigned procedure within 30 days after randomization). Because the periprocedural period was relatively short, which minimized the need for censoring, event proportions and the absolute differences in event proportions were calculated as the percentage of patients with events. For the 4-year study period, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. Hazard ratios for the periprocedural period were based on data for all patients, censored at the end of the periprocedural period. All hazard ratios were adjusted for age, symptomatic status, and sex. P values were calculated on the basis of the significance of the hazard ratio (per study protocol). For death, stroke, and myocardial infarction end points, patients may have had more than one event (e.g., fatal stroke was counted as both a death and a stroke, and patients may have had an ipsilateral stroke followed by a nonipsilateral stroke). † Because of the small number of events, a univariate proportional-hazards model was used to estimate the hazard ratio for death during the periprocedural period, the P value for minor nonipsilateral stroke during the periprocedural period, and the P value for major nonipsilateral stroke during the 4-year study period. ‡ Absolute treatment effect, hazard ratio, and P value for major nonipsilateral stroke were not available (NA) because of the small number of events, resulting in unreliable estimates.
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differential rates of withdrawal from the study in the two groups. Secondary aims included estimating the modification of the treatment effect by symptomatic status, sex, and age, which were assessed through inclusion of the interaction terms in the proportional-hazards models (as a single indicator variable for sex and symptomatic status and a linear term for age). The analyses of age were planned before data analysis began but were not described in the study protocol. Longitudinal random-effect growth-curve models 20 were used to evaluate the effect of periprocedural events on health status at 1 year, as assessed with the use of the SF-36 physical and mental health scales. These models were adjusted for symptomatic status, sex, age, and baseline health status.
R esult s
Study Population and Treatments
From December 2000 through July 2008, a total of 2522 patients were randomly assigned to one of the two treatments (Fig. 1) . After randomization, among the 1271 patients randomly assigned to undergo carotid-artery stenting, 36 (2.8%) withdrew consent, 73 (5.7%) underwent carotid endarterectomy, and 33 (2.6%) were lost to followup; among the 1251 patients assigned to carotid endarterectomy, 64 (5.1%) withdrew consent, 13 (1.0%) underwent carotid-artery stenting, and 47 (3.8%) were lost to follow-up.
Quality-control and site-monitoring activities resulted in the detection of irregular data from one center. The principal investigator and the Office of Research Integrity of the Department of Health and Human Services were notified and subsequently determined that some data were fabricated. All data from this center (which had enrolled 9 patients undergoing carotid-artery stenting and 11 undergoing carotid endarterectomy) were excluded before any analyses were performed, resulting in a cohort of 2502 patients for all analyses.
Dyslipidemia was more common among patients in the endarterectomy group than among those in the stenting group (85.8% vs. 82.9%, P = 0.048), both groups had high rates of vascular risk factors, and more than 80% of patients had severe stenosis ( procedure was 6 days for carotid-artery stenting and 7 days for carotid endarterectomy. Stenting was performed with embolic protection in 96.1% of patients assigned to the stenting group, and endarterectomy was performed with the use of general anesthesia in 90.0% of patients assigned to the endarterectomy group. The median duration of follow-up was 2.5 years. During that time, the level or prevalence of selected risk factors remained similar between the two treatment groups, except for current smoking, the prevalence of which was similar at baseline (26.4% with stenting and 26.1% with endarterectomy) but for which differences developed during follow-up (21.8% with stenting vs. 13.8% with endarterectomy, P = 0.03) ( Table 4 in the Supplementary Appendix).
Primary End Point
There was no significant difference in the estimated 4-year rates of the primary end point between carotid-artery stenting and carotid endarterectomy (7.2% and 6.8%, respectively; hazard ratio for stenting, 1.11; 95% confidence interval [CI], 0.81 to 1.51; P = 0.51) ( Table 2 and Fig. 2A) . Findings from the multiple-imputation analysis suggested that the withdrawal of patients in each group did not introduce bias. Of the end-point events, 13 strokes were fatal (7 in the stenting group and 6 in the endarterectomy group), and 1 myocardial infarction was fatal (in the endarterectomy group). During the periprocedural period, the incidence of the primary end point was similar with carotidartery stenting and carotid endarterectomy (5.2 and 4.5%, respectively; hazard ratio for stenting, 1.18; 95% CI, 0.82 to 1.68; P = 0.38), although the rates of the individual end points differed between the stenting group and the endarterectomy group (death, 0.7% vs. 0.3%; P = 0.18; stroke, 4.1% vs. 2.3%; P = 0.01; myocardial infarction, 1.1% vs. 2.3%; P = 0.03) ( Table 2 , and Fig. 1 in the Supplementary Appendix). After the periprocedural period, the incidence of ipsilateral stroke was similarly low with carotid-artery stenting and with carotid endarterectomy (2.0% and 2.4%, respectively; P = 0.85). Prespecified analyses did not show a modification of the treatment effect by symptomatic status (P = 0.84) or by sex (P = 0.34) ( Table 5 in the Supplementary Appendix). However, an interaction between age and treatment efficacy was detected (P = 0.02) (Fig. 2B and 2C) , with a crossover at an age of approximately 70 years; carotid-artery stenting tended to show greater efficacy at younger ages, and carotid endarterectomy at older ages.
Prespecified Secondary Analyses
During the periprocedural period, rates of the primary end point did not differ significantly between the stenting group and the endarterectomy group among symptomatic patients (6.7% vs. 5.4%; hazard ratio for stenting, 1.26; 95% CI, 0.81 to 1.96) or among asymptomatic patients (3.5% vs. 3.6%; hazard ratio, 1.02; 95% CI, 0.55 to 1.86) (Table 3). Cranial-nerve palsies were less frequent during the periprocedural period with carotid-artery stenting (0.3%, vs. 4.7% with carotid endarterectomy; hazard ratio, 0.07; 95% CI, 0.02 to 0.18). Additional serious adverse events are detailed in Table 6 in the Supplementary Appendix. The 4-year rate of stroke or death was 6.4% in the stenting group as compared with 4.7% in the endarterectomy group (hazard ratio, 1.50; 95% CI, 1.05 to 2.15; P = 0.03); the respective rates were 8.0% and 6.4% among symptomatic patients (hazard ratio, 1.37; 95% CI, 0.90 to 2.09; P = 0.14) and 4.5% and 2.7% among asymptomatic patients (hazard ratio, 1.86; 95% CI, 0.95 to 3.66; P = 0.07).
Post Hoc Analyses
Longitudinal growth-curve models were used to estimate the effect of periprocedural stroke and myocardial infarction on health status at 1 year ( Fig. 2 and 3 in the Supplementary Appendix). Major stroke and minor stroke were found to have an effect on physical health at 1 year, according to the SF-36 physical component scale (mean effect estimates, −15.8 points [95% CI, −25.1 to −6.4] and −4.5 points [95% CI, −7.9 to −1.2], respectively), whereas the effect of periprocedural myocardial infarction was less certain (mean effect estimate, −3.0 points [95% CI, −7.1 to 1.1]). Minor stroke had a significant effect on mental health at 1 year, as measured on the SF-36 mental component scale (mean effect estimate, -3.4 points [95% CI, −6.3 to −0.5]). The likelihood of the primary end point was not significantly affected by the medical specialty of the interventionist performing the carotidartery stenting (P = 0.51) ( Table 7 in the Supplementary Appendix). 9 
Discussion
Our CREST results indicate that carotid-artery stenting and carotid endarterectomy were associated with similar rates of the primary composite outcome -periprocedural stroke, myocardial infarction, or death and subsequent ipsilateral stroke -among men and women with either symptom-atic or asymptomatic carotid stenosis. However, the incidence of periprocedural stroke was lower in the endarterectomy group than in the stenting group, whereas the incidence of periprocedural myocardial infarction was lower in the stenting group. These countervailing effects during the periprocedural period resulted in similar rates of the primary outcomes because the rates of events after the periprocedural period were similar in the two groups. Although previous studies have indicated that both stroke and myocardial infarction are associated with substantial morbidity and mortality, 21, 22 quality-of-life analyses among survivors at 1 year in our trial indicate that stroke had a greater adverse effect on a broad range of health-status domains than did myocardial infarction.
The selection of patients for either carotidartery stenting or carotid endarterectomy may require attention to age, with younger patients having a slightly better outcome with carotidartery stenting and older patients having a better outcome with carotid endarterectomy. 23 The association between older age and increased risk of adverse events after carotid-artery stenting was seen in our lead-in cohort, 9 the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial (Current Controlled Trials number, ISRCTN57874028), 6 and the International Carotid Stenting Study (ICSS; ISRCTN25337470). 24 An effect of age on differences between carotidartery stenting and carotid endarterectomy was found in the SPACE trial 25 as well as in our study. Mechanisms underlying the increased risk with carotid-artery stenting in very elderly patients probably include vascular tortuosity and severe vascular calcification. 23 The periprocedural outcomes for carotid-artery stenting and carotid endarterectomy reported here are the best reported from a randomized, carotidrevascularization study that incorporated pre-and postprocedural medical, neurologic, ECG, and biomarker evaluations (Table 3 ). The rate of stroke or death among our symptomatic patients after carotid-artery stenting (6.0%) was lower than the corresponding rates in the SPACE trial (6.8%, not including nonipsilateral stroke), the Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial (ClinicalTrials.gov number, NCT00190398) (9.6%), and ICSS (7.4%). The rate of stroke or death among our symptomatic patients after carotid endarterectomy (3.2%) was also lower than the cor- The primary end point was a composite of stroke, myocardial infarction, or death from any cause during the periprocedural period or ipsilateral stroke within 4 years after randomization. Panel A shows the Kaplan-Meier curves for patients undergoing carotid-artery stenting (CAS) and those undergoing carotid endarterectomy (CEA) in whom the primary end point did not occur, according to year of follow-up. Panel B shows the hazard ratios for the primary end point, as calculated for the CAS group versus the CEA group, according to age at the time of the procedure. The hazard ratios were estimated from the proportional-hazards model with adjustment for sex and symptomatic status. Dashed lines indicate the 95% confidence intervals. Panel C shows the numbers of patients in each group in whom the primary end point occurred during the study, according to age group. * The 1181 asymptomatic patients consisted of 594 patients in the carotid-artery stenting (CAS) group and 587 in the carotid endarterectomy (CEA) group. The 1321 symptomatic patients consisted of 668 in the CAS group and 653 in the CEA group. The periprocedural period was defined, according to the study protocol, as the 30-day period after the procedure (for all patients who underwent the assigned procedure within 30 days after randomization) or the 36-day period after randomization (for all patients who did not undergo the assigned procedure within 30 days after randomization). Because the periprocedural period is relatively short, which minimizes the need for censoring, event proportions and the absolute differences in event proportions were calculated as the percentage of patients with events. For the 4-year study period, proportions reflecting the absolute efficacy of CAS over that of CEA were based on Kaplan-Meier survival estimates at the end of the 4 years. Hazard ratios for the periprocedural period were based on data for all patients, censored at the end of the periprocedural period. All hazard ratios were adjusted for age, symptomatic status, and sex. P values were calculated on the basis of the significance of the hazard ratio (per study protocol). For death, stroke, and myocardial infarction end points, patients could have had more than one event (e.g., fatal stroke was counted as both a death and a stroke, and patients may have had an ipsilateral stroke followed by a nonipsilateral stroke).
responding percentage in SPACE (6.3%) and was similar to the corresponding percentage in EVA-3S (3.9%) as well as that in ICSS (3.4%); in ICSS, patients were not formally examined per protocol before or after the procedure or at 30 days. Among asymptomatic patients, the rate of stroke or death in the carotid-artery stenting group in our trial (2.5%) was similar to that in the Asymptomatic Carotid Atherosclerosis Study (ACAS) (2.3%, excluding patients older than 79 years) 8 and was lower than that in the Asymptomatic Carotid Surgery Trial (ACST; ISRCTN26156392) (3.1%), 26 and the rate of stroke and death in our carotidendarterectomy group (1.4%) was lower than that in ACAS and ACST. The improved periprocedural outcomes in CREST as compared with previous trials may reflect the effective surgeon credentialing, assimilation of evolving endovascular technology, and rigorous training and credentialing of carotidartery stenting operators. 9 The differential results for myocardial infarction and stroke offer opportunities for improvement. To reduce the risk of stroke after carotid-artery stenting, improvements in training and technique, embolic protection and stent design, and patient selection (especially among patients older than 70 years of age) hold promise. 23, 27 To reduce the risk of myocardial infarction after carotid endarterectomy, more detailed preoperative cardiovascular evaluation and the use of dual antiplatelet therapy, statins, 28 cardioprotective pharmacotherapy, 29 or local anesthesia could be investigated.
The clinical durability of carotid-artery stenting and carotid endarterectomy is important. The rates of ipsilateral stroke during our follow-up period -2.0% with carotid-artery stenting and 2.4% with carotid endarterectomy -are similar to the rates in the SPACE trial and EVA-3S, suggesting excellent durability for up to 4 years. Because the life expectancy of our average-aged patient is 15 years after the procedure, 30 outcomes are being assessed in CREST out to 10 years.
The CREST study does have limitations. The certification requirements were important for patient safety, but they limit the generalizability of the results and conclusions to similarly qualified operators. One interventional carotid-artery stenting system was used. Improvements were incorporated into that system as technology evolved. Although the use of one system facilitated standardization, external validity may have been affected by our prohibition on the use of other stent systems. The addition of asymptomatic patients and the anticipated lower event rate for that group had the potential to compromise the statistical power. However, that lower event rate was offset by the higher number of events associated with the extended enrollment and follow-up periods. The use of medical therapy alone was not studied, sharply limiting our ability to generalize the results. For example, the rates of ipsilateral and contralateral stroke were similar in the two groups after the periprocedural period. For asymptomatic patients, this similarity could indicate that revascularization is durable or that asymptomatic carotid stenosis is benign if treated medically.
In conclusion, carotid revascularization performed by highly qualified surgeons and interventionists is effective and safe. Stroke was more likely after carotid-artery stenting. Myocardial infarction was more likely after carotid endarterectomy, but the effect on the quality of life was less than the effect of stroke. Younger patients had slightly fewer events after carotid-artery stenting than after carotid endarterectomy; older patients had fewer events after carotid endarterectomy. The low absolute risk of recurrent stroke suggests that both carotid-artery stenting and carotid endarterectomy are clinically durable and may also reflect advances in medical therapy.
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